Table 4.
Effectiveness assessments by investigators and children/parents by means of IMOS.
| Assessment of IMOS | Investigator's assessment | χ 2-test | Children's/parents' assessment | χ 2-test | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ZinCyp-3-02 N = 89 |
Control N = 90 |
ZinCyp-3-02 N = 89 |
Control N = 90 |
|||||||
| N | % | N | % | N | % | N | % | |||
| No complaints | 14 | 15.7 | 5 | 5.6 | p < 0.0001 | 20 | 22.5 | 6 | 6.7 | p < 0.0001 |
| Major improvement | 40 | 44.9 | 17 | 18.9 | 35 | 39.3 | 16 | 17.8 | ||
| Improvement | 31 | 34.8 | 26 | 28.9 | 30 | 33.7 | 29 | 32.2 | ||
| No change | 3 | 3.4 | 42 | 46.7 | 3 | 3.4 | 39 | 43.3 | ||
| Deterioration | 1 | 1.1 | 0 | 0.0 | 1 | 1.1 | 0 | 0.0 | ||
Measurements at V4 (day 28) in the final overall evaluation. IMOS: Integrative Medicine Outcome Scale; χ 2: Chi-square. Intention-to-treat analysis.